SG160424A1 - Compositions of influenza viral proteins and methods of use thereof - Google Patents
Compositions of influenza viral proteins and methods of use thereofInfo
- Publication number
- SG160424A1 SG160424A1 SG201001924-8A SG2010019248A SG160424A1 SG 160424 A1 SG160424 A1 SG 160424A1 SG 2010019248 A SG2010019248 A SG 2010019248A SG 160424 A1 SG160424 A1 SG 160424A1
- Authority
- SG
- Singapore
- Prior art keywords
- compositions
- methods
- influenza viral
- viral proteins
- fusion proteins
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 206010022000 influenza Diseases 0.000 title abstract 2
- 108010067390 Viral Proteins Proteins 0.000 title 1
- 102000037865 fusion proteins Human genes 0.000 abstract 2
- 108020001507 fusion proteins Proteins 0.000 abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 102000018697 Membrane Proteins Human genes 0.000 abstract 1
- 108010052285 Membrane Proteins Proteins 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 244000052769 pathogen Species 0.000 abstract 1
- 230000001717 pathogenic effect Effects 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6075—Viral proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63835004P | 2004-12-21 | 2004-12-21 | |
| US63825404P | 2004-12-21 | 2004-12-21 | |
| US64506705P | 2005-01-19 | 2005-01-19 | |
| US65320705P | 2005-02-15 | 2005-02-15 | |
| US66687805P | 2005-03-31 | 2005-03-31 | |
| US68207705P | 2005-05-18 | 2005-05-18 | |
| US74120205P | 2005-11-30 | 2005-11-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG160424A1 true SG160424A1 (en) | 2010-04-29 |
Family
ID=36272492
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG201001924-8A SG160424A1 (en) | 2004-12-21 | 2005-12-21 | Compositions of influenza viral proteins and methods of use thereof |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP1831259A2 (enExample) |
| JP (1) | JP2008524261A (enExample) |
| AU (2) | AU2005319141B8 (enExample) |
| BR (1) | BRPI0519705A2 (enExample) |
| CA (1) | CA2593746A1 (enExample) |
| MX (1) | MX2007007586A (enExample) |
| NZ (1) | NZ556004A (enExample) |
| SG (1) | SG160424A1 (enExample) |
| WO (1) | WO2006069262A2 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR052195A1 (es) | 2005-01-19 | 2007-03-07 | Vaxinnate Corp | Composiciones de patrones moleculares asociados a patogenos en metodos de uso |
| ES2555544T3 (es) | 2006-03-07 | 2016-01-04 | Vaxinnate Corporation | Composiciones que incluyen hemaglutinina, métodos de preparación y métodos de uso de las mismas |
| EP2012829A4 (en) * | 2006-04-24 | 2010-04-21 | Protelix Inc | PROCESS FOR PRODUCING VIRAL VACCINE AND THERAPEUTIC PEPTIDE ANTIGENS |
| EP2517723B1 (en) * | 2006-09-18 | 2019-11-06 | The Board of Trustees of The University of Arkansas | Compositions and methods of enhancing immune responses |
| EP1925318A1 (en) * | 2006-11-20 | 2008-05-28 | Paul-Ehrlich-Institut | Recombinant modified vaccinia virus Ankara (MVA)-based vaccine for the avian flu |
| WO2008157419A2 (en) * | 2007-06-13 | 2008-12-24 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Immunogenic peptides of influenza virus |
| WO2009016639A2 (en) | 2007-08-02 | 2009-02-05 | Biondvax Pharmaceuticals Ltd. | Multimeric multiepitope influenza vaccines |
| GB0720250D0 (en) | 2007-10-17 | 2007-11-28 | Univ Edinburgh | Immunogenic compositions containing escherichia coli h7 flagella and methods of use thereof |
| EP2223934B1 (en) * | 2007-11-14 | 2012-10-03 | Institute Of Microbiology, Chinese Academy Of Sciences | Polypeptides for inhibiting influenza virus infection |
| SG190562A1 (en) | 2008-04-18 | 2013-06-28 | Vaxinnate Corp | Deletion mutants of flagellin and methods of use |
| WO2010115229A1 (en) | 2009-04-09 | 2010-10-14 | The University Of Melbourne | Immunogenic composition and uses thereof |
| MX348663B (es) * | 2009-09-08 | 2017-05-26 | Inst Tecnologico Estudios Superiores Monterrey | Proceso de producción de una vacuna recombinante, dicha vacuna expresable en cepas de escherichia coli y su uso para combatir la influenza a h1ni1 brote 2009. |
| US20130095130A1 (en) * | 2010-01-06 | 2013-04-18 | Vaxinnate Corporation | Methods and Compositions for Providing Protective Immunity in the Elderly |
| CN102811734B (zh) | 2010-01-21 | 2016-02-10 | 阿肯色大学评议会 | 增强免疫应答的疫苗载体和方法 |
| CN103118709A (zh) * | 2010-03-26 | 2013-05-22 | 新兴产品开发盖瑟斯堡有限公司 | 流感病毒基质2蛋白的胞外域、其表达系统和应用 |
| GB201009273D0 (en) * | 2010-06-03 | 2010-07-21 | Glaxosmithkline Biolog Sa | Novel vaccine |
| CA2811957C (en) | 2010-09-22 | 2019-04-16 | The University Of Melbourne | Soluble tlr2 moiety for use in the treatment or prevention of respiratory conditions associated with infectious agents |
| WO2012114323A1 (en) | 2011-02-22 | 2012-08-30 | Biondvax Pharmaceuticals Ltd. | Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines |
| US8932598B2 (en) | 2012-08-28 | 2015-01-13 | Vaxinnate Corporation | Fusion proteins and methods of use |
| WO2014070848A1 (en) * | 2012-11-05 | 2014-05-08 | Georgia State University Research Foundation | Universal influenza vaccine based on heterologous multiple m2e proteins |
| RU2571944C1 (ru) * | 2014-10-17 | 2015-12-27 | Общество с ограниченной ответственностью "НТфарма" | Противогриппозная вакцина широкого спектра действия против птичьего гриппа а на основе эктодомена белка м2 |
| IL275360B2 (en) | 2017-12-21 | 2023-10-01 | Axelia Oncology Pty Ltd | Optimal compounds |
| NZ783377A (en) | 2019-06-26 | 2026-03-27 | Ena Respiratory Pty Ltd | Pegylated novel molecules for agonising tlr2 |
| AU2022338350A1 (en) * | 2021-09-02 | 2024-02-29 | Ena Respiratory Pty Ltd | Formulation |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7569225B2 (en) * | 2002-08-12 | 2009-08-04 | The Council Of The Queensland Institute Of Medical Research | Immunogenic lipopeptides comprising T-helper and B-cell epitopes |
| EP1603590A4 (en) * | 2003-03-07 | 2008-08-27 | Merck & Co Inc | INFLUENZA VIRUS VACCINE |
-
2005
- 2005-12-21 NZ NZ556004A patent/NZ556004A/en not_active IP Right Cessation
- 2005-12-21 AU AU2005319141A patent/AU2005319141B8/en not_active Ceased
- 2005-12-21 EP EP05855253A patent/EP1831259A2/en not_active Withdrawn
- 2005-12-21 WO PCT/US2005/046662 patent/WO2006069262A2/en not_active Ceased
- 2005-12-21 BR BRPI0519705-8A patent/BRPI0519705A2/pt not_active IP Right Cessation
- 2005-12-21 MX MX2007007586A patent/MX2007007586A/es not_active Application Discontinuation
- 2005-12-21 JP JP2007547054A patent/JP2008524261A/ja active Pending
- 2005-12-21 SG SG201001924-8A patent/SG160424A1/en unknown
- 2005-12-21 CA CA002593746A patent/CA2593746A1/en not_active Abandoned
-
2010
- 2010-01-07 AU AU2010200048A patent/AU2010200048A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2593746A1 (en) | 2006-06-29 |
| BRPI0519705A2 (pt) | 2009-03-10 |
| WO2006069262A2 (en) | 2006-06-29 |
| JP2008524261A (ja) | 2008-07-10 |
| EP1831259A2 (en) | 2007-09-12 |
| AU2005319141B8 (en) | 2010-03-18 |
| MX2007007586A (es) | 2007-12-10 |
| WO2006069262A3 (en) | 2007-02-01 |
| AU2010200048A1 (en) | 2010-01-28 |
| AU2005319141B2 (en) | 2010-02-18 |
| NZ556004A (en) | 2010-05-28 |
| AU2005319141A1 (en) | 2006-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2007007586A (es) | Composiciones de proteinas de virus de gripe y metodos de uso de las mismas. | |
| WO2003083058A3 (en) | Replikin peptides in rapid replication of glioma cells and in influenza epidemics | |
| IL187168A (en) | Proteins or polypeptides which comprise two identical nanobodies against von willebrand factor, methods for their preparation, pharmaceutical compositions comprising them and their uses | |
| FR20C1016I1 (enExample) | ||
| EP1490094A4 (en) | ANTIBODY FUSION PROTEINS: EFFECTIVE ADJUVANTIES IN PROTEIN VACCINATION | |
| WO2004084805A3 (en) | Acetylated tat polypeptides and methods of use thereof | |
| CY1119243T1 (el) | Φαρμακοτεχνικες μορφες ανταγωνιστη του vegf | |
| EA200801798A1 (ru) | Виросомоподобные везикулы, содержащие антигены, производные от gp41 | |
| PL1615945T3 (pl) | Sposoby glikopegylacji i białka/peptydy wytwarzane tymi sposobami | |
| PL1699822T3 (pl) | Białka fuzyjne IL-7 z częściami przeciwciała, ich otrzymywanie oraz ich zastosowanie | |
| SG165353A1 (en) | Improved human interferon molecules and their uses | |
| WO2004080403A3 (en) | Influenza virus vaccine | |
| WO2007053188A3 (en) | Production of multivalent virus like particles | |
| WO2008134697A3 (en) | Prrsv vaccins based on gp5 proteins | |
| DE602005022056D1 (de) | Polypeptidsequenzen, die an der modulation des immunsupppressiven effekts viraler proteine beteiligt sind | |
| ATE551069T1 (de) | Mucin-fusionspolypeptid-vakzine, zusammensetzungen und ihre verwendung | |
| WO2005118813A3 (en) | Nucleic acids, polypeptides, methods of expression, and immunogenic compositions associated with sars corona virus spike protein | |
| WO2006023665A3 (en) | Il-1 antagonist formulations | |
| WO2002077012A3 (en) | Human papilloma virus immunoreative peptides | |
| DE60139544D1 (de) | Veränderte, fluoreszierende proteine | |
| WO2006073422A3 (en) | Activation of natural killer (nk) cells and methods of use | |
| ATE389397T1 (de) | Adjuvante zusammensetzungen | |
| WO2005013904A3 (en) | Sars nucleic acids, proteins, vaccines, and uses thereof | |
| WO2001094949A3 (en) | Soluble cd1 compositions and uses thereof | |
| TW200509964A (en) | VP1 of foot-and-mouth disease virus |